Meaxin

Imatinib, the active ingredient in Meaxin, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors in adult patients, targeting specific oncogenic kinases.

GNH USA supplies Meaxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant facilities and community pharmacies worldwide, providing consistent product quality, regulatory adherence and reliable logistics for oncology therapeutics.

Meaxin (imatinib) acts on malignant cells driven by specific tyrosine‑kinase pathways.

Chronic myeloid leukemia (CML): achieves disease control and prolongs survival. Gastrointestinal stromal tumor (GIST): achieves tumor shrinkage and disease stabilization.

Imatinib may cause a range of adverse reactions.

Common Side Effects: - Nausea - Peripheral edema - Muscle cramps or pain - Fatigue

Serious or Rare Side Effects: - Severe neutropenia or leukopenia - Hepatotoxicity (liver injury) - Cardiac failure or reduced left‑ventricular function

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check transaminases and bilirubin periodically. - Evaluate cardiac status: baseline ECG and echocardiogram for patients with cardiac risk. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at below 25°C: keep in the original pack, protect from moisture.

Imatinib interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) - Antacids containing magnesium or aluminum that may reduce absorption

Moderate Interactions (Monitor Closely): - Warfarin (may increase INR) - QT‑prolonging agents (risk of arrhythmia) - Live vaccines (potentially reduced efficacy)